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Abbreviations 
 
MIAMI, Markers of Inflammation and Atorvastatin effect in previous Myocardial Infarction 
CAD= coronary artery disease 
ACS= acute coronary syndrome 
BP= blood pressure 
BMI= body mass index 
C-IMT= carotid intima media thickness 
CC-IMTmean= Mean IMT of common carotids 
Bif-IMTmean= Mean IMT of bifurcations 
ICA-IMTmean= Mean IMT of internal carotid arteries 
IMTmean= Mean IMT of the whole carotid tree 
IMTmax= Max IMT of the whole carotid tree 
hs-CRP= high sensitive C-reactive protein 
TNF-α= tumour necrosis factor-α 
IL= interleukin 
sCD40L= soluble CD40 ligand 
MMP-9= matrix metalloproteinase-9 
TFPI-free= free tissue factor pathway inhibitor 
TFPI-total= total tissue factor pathway inhibitor 
sICAM-1= soluble intercellular adhesion molecule-1 
sVCAM-1= soluble vascular cell adhesion molecule-1 
sE-selectin= soluble E-selectin  
vWF= von Willebrand factor 
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Abstract 
Background and aims: MIAMI is a prospective multicenter clinical study designed to 
investigate the relationship between changes in carotid intima media thickness (C-IMT) 
and changes in circulating markers of inflammation, thrombosis and endothelial activation 
in stable coronary patients treated for 20±3.7 months with 20 mg/day atorvastatin.  
Methods and results: 85 subjects had their C-IMT, blood lipids and soluble markers 
measured at baseline, at the 12th month and at the end of the study. Almost all soluble 
markers decreased upon treatment except for high-sensitivity C-reactive protein (hs-CRP), 
interleukin-18 (IL-18), tissue factor pathway inhibitor-free (TFPI-free) and soluble vascular 
cell adhesion molecules-1 (sVCAM-1) which did not change significantly, and interleukin-6 
(IL-6), tumor necrosis factor-α (TNF-α) and soluble CD40 ligand (sCD40L) which 
increased. sCD40L, fibrinogen, tissue factor pathway inhibitor-total (TFPI-total), soluble 
intercellular adhesion molecules-1 (sICAM-1), sE-selectin, interleukin-8 (IL-8) and von 
Willebrand factor (vWF) changed significantly even after application of the Bonferroni 
correction for multiple comparisons. Changes in lipids did not correlate with C-IMT 
regression either when considered singly or when combined in a lipid score. Changes in 
soluble markers correlated poorly with C-IMT regression when analyzed singly, but 
strongly when combined in relevant composite scores (inflammation/coagulation score, 
endothelial activation score, soluble markers score and total score). 
Conclusion: in patients with stable coronary artery disease treated with moderate doses 
of atorvastatin, carotid IMT regression correlated with changes of inflammation, 
thrombosis and endothelial activation profiles. 
 
 
 5
Introduction 
Large, randomized, controlled trials have documented that cholesterol-lowering therapy 
with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduces the risk 
of cardiovascular events across a wide range of plasma cholesterol levels in patients with 
or without a history of coronary artery disease (CAD).[1] Besides their inhibition of 
cholesterol synthesis, the beneficial effects of statins have been attributed in part to their 
suppression of the pro-inflammatory/pro-thrombotic pathways involved in 
atherothrombosis.[2]  
The MIAMI study (Markers of Inflammation and Atorvastatin effect in previous 
Myocardial Infarction), is a prospective, open-label, multicenter study, designed to 
investigate the relationship between changes in carotid intima media thickness (C-IMT) 
and changes in circulating markers of inflammation, coagulation and endothelial activation 
in patients with stable CAD treated with a moderate dose of atorvastatin (20 mg/day) for 
up to two years. The cross-sectional relationship between the soluble markers measured 
and the extent of carotid atherosclerosis at baseline has been previously reported.[3] We 
describe here the results of the longitudinal part of the study. 
 
Methods 
 
Study population 
The design, methods and preliminary results of MIAMI study were as previously 
described.[3] Briefly, 85 patients with stable CAD (i.e., previous myocardial infarction more 
than two months before entry) were enrolled in 4 cardiology centers in Milan (Italy).  
All patients were statin-naïve. Subjects already taking lipid-lowering medication 
required an 8-week washout period before enrolment. Ethical issues on this washout 
period were previously described.[3] The study complies with the Declaration of Helsinki 
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and was approved by 5 independent ethics committees. All patients gave written informed 
consent. 
Because all patients had a previous myocardial infarction and because clinical trials 
have demonstrated substantially improved outcomes with statins, it was deemed ethically 
unacceptable to randomize these patients to placebo. Accordingly, all patients were 
assigned to an active treatment with 20 mg/day atorvastatin (kindly provided by Pfizer 
Italia).  
Patients were maintained on their other medications including aspirin, β-blockers, 
diuretics and low-dosage ACE inhibitors, without change, throughout the study.  
A baseline evaluation included demographic information, medication use, smoking 
and alcohol consumption, a physical examination with blood pressure, body mass index 
and fasting blood sampling. ECG was also recorded. Blood samples for central laboratory 
assay of lipid profile and plasma markers were collected at month 0, 12, and 24, at the 
same time as C-IMT measurement. Patients not reaching the 24th month follow-up 
underwent their last visit within the two weeks preceding the end of the study. 
 
Carotid IMT  
Carotid ultrasound was done by a single operator (M.A.) using an ACUSON Aspen system 
equipped with a 10-13 MHz linear array probe, and recorded on sVHS videotapes. The far 
wall of the left and right common carotid (CC), bifurcation (Bif) and internal carotid artery 
(ICA) were visualized in anterior, lateral and posterior projections.  
The ultrasonic variables considered were the mean IMT of the common carotids 
(CC-IMTmean), bifurcations (Bif-IMTmean), internal carotid arteries (ICA-IMTmean) and the 
mean and maximum of the whole carotid tree (IMTmean and IMTmax). All these ultrasonic 
variables incorporate plaque(s). 
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Ultrasonic measurements were performed by 2 readers (A.R. and E.O.) unaware of 
which trial they were evaluating, using specific software (M’Ath, Metris SRL France) that 
allows automatic edge detection of echogenic lines of the intima-media complex. 
Progression of the C-IMT was estimated by assuming a linear trend with time. The mean 
of 2 independent C-IMT determinations carried out 2 weeks apart was adopted for 
statistical analyses. Readings were taken at the far wall of the whole CC, Bif, and the first 
proximal cm of the ICA. The 2 independent C-IMT determinations were also used for the 
repeatability evaluation. The absolute differences (mean±SD) between baseline replicate 
scans were 0.012±0.010, 0.044±0.045, 0.043±0.046, 0.020±0.025 and 0.085±0.109 mm 
for CC-IMTmean, Bif-IMTmean, ICA-IMTmean, IMTmean and IMTmax, respectively. The same 
figures obtained at the last visit were 0.011±0.009 mm, 0.041±0.037 mm, 0.036±0.035 
mm, 0.015±0.013 mm, 0.080±0.087 mm, respectively. 
All baseline common carotid scans were measured again at the end of the study in 
order to assess whether a systematic change in readers’ skill could have biased the 
estimate of IMT progression; no systematic differences were found (0.765±0.142 and 
0.763±0.141 mm; p=0.2). 
 
Laboratory tests 
As a panel of inflammation and coagulation markers, plasma levels of high-sensitivity C-
reactive protein (hs-CRP), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-18 (IL-18), soluble CD40 ligand (sCD40L), matrix 
metalloproteinase-9 (MMP-9), fibrinogen, free and total tissue factor pathway inhibitor 
(TFPI-free and TFPI-total) were measured. Soluble intercellular adhesion molecule-1 
(sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin  (sE-
selectin) and von Willebrand factor (vWF) were measured as endothelial cell activation 
markers. All variables were measured by commercial kits (all intra- and inter-assay 
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coefficients of variation: <6%). Since changes from baseline were maintained over the 
course of the study, the averages between the 12th month and last visit were reported as 
on-treatment values. 
To assess whether changes in carotid IMT correlated with the global variations of 
inflammation/coagulation status, all markers of inflammation and coagulation were 
combined in an inflammation/coagulation score, computed by dichotomizing the data 
around each median value (see below). Similarly, all markers of endothelial activation 
were combined in an endothelial activation score and lipids were combined in a lipid score. 
A global soluble markers score (including all markers of inflammation, coagulation and 
endothelial activation) was also devised. Finally, in order to investigate the effect of 
changes of all variables considered, including lipids, a total score was also computed. 
 
Statistical analysis 
Concerning the main end point of the study, the sample size of 85 patients should give an 
assessment with a power of 80% and an alpha error of 0.003 (accounting for 18 multiple 
comparisons with Bonferroni correction), a correlation coefficient (r) of at least 0.4 between 
each soluble marker and carotid IMT. Alternatively, our sample size allowed a power of 
80% to detect as significant, with an alpha error of 0.05, a regression of IMTmean of at least 
-0.012 mm/yr, assuming a standard deviation of 0.04. 
Continuous data are expressed as mean±SD and median (interquartile range), 
whereas categorical data are expressed as number or percentage. Variables were tested 
for normal distribution using the Kolmogorow-Smirnov test. Variables with a skewed 
distribution were log-transformed before analysis. Variations between on-treatment and 
baseline values were assessed by paired sample t-test.  
Correlations among changes of plasma levels of lipids and soluble markers and of 
IMT values were analyzed by Pearson correlation. Partial correlation between soluble 
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markers and selected carotid IMT variables were computed adjusting for variations in total- 
and HDL-cholesterol and triglycerides. Multiple regression analysis with stepwise selection 
was used to identify variables independently associated with IMT changes.  
To achieve the above-mentioned combined scores (lipid-score, 
inflammation/coagulation score, endothelial activation score, soluble markers score, and 
total score), variables were expressed as delta-values (on-treatment minus baseline) and 
were transformed into dichotomous variables by assigning a value of 1 for changes above 
the median and 0 for changes equal or below (except for HDL-C, for which the opposite 
was done). Each score was then computed by averaging the appropriate dichotomized 
variables.  
Thus, lower scores indicate a greater on-treatment improvement of the specific “status” 
considered and high values a poorer improvement or worsening. 
The use of combined scores instead of single variables adds power to the statistical 
analyses and limits the inflation of type 1 error, which is otherwise a problem when single 
variables are analyzed because of the high number of statistical tests performed. In the 
score analyses, we could employ a less stringent threshold for significance of p=0.01. 
Statistical analyses were done using SAS V8.2 software (SAS Institute Inc., Cary, NC, 
USA). 
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Results 
Patients 
Between June 2002 and December 2004, about 600 patients were screened and 85 who 
met all the inclusion/exclusion criteria received the treatment.  
One patient who died after 18 months from enrolment for reasons not related to 
cardiovascular disease was included into the analyses because data from the 12th month 
visit were available. No other serious adverse events were observed. 3 patients dropped 
out immediately after the baseline visit (1 by withdrawing informed consent and 2 because 
of a newly diagnosed cancer) and were excluded from the analyses. Baseline 
demographic characteristics and concomitant medications of the enrolled patients are 
shown in table 1. No change in concomitant medications during follow-up was recorded. 
Compliance, defined as acceptable if at least 85% of study medication was consumed, 
was assessed every 12 months and averaged 90.1%. 
 
Follow-up  
The study was finally approved on 04/06/2003 and had to be concluded by 01/01/2006. 
Since the period of patients’ recruitment was longer than foreseen, only 28 patients (34%) 
reached 24 months’ follow-up, 31 (37.8%) had a follow-up of at least 18 months, 11 
(13.4%) of at least 15 months and 12 (14.6%) of at least 12 months (Figure 1). The mean 
follow-up of the whole group was 20±3.7 months. 
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Baseline and on-treatment values of lipids and soluble markers 
Table 2 shows the baseline and on-treatment values of lipids and soluble markers. As 
expected, atorvastatin induced a significant and optimal reduction in total- and LDL-
cholesterol and triglycerides and a moderate (4%) increase of HDL-cholesterol.  
Almost all on-treatment soluble markers decreased from baseline, except for hs-
CRP, IL-18, TFPI-free and sVCAM-1 which did not change significantly, and IL-6, TNF-α 
and sCD40L which were increased. After applying the Bonferroni correction sCD40L, 
fibrinogen, TFPI-total, sICAM-1, sE-selectin and vWF were significantly changed, whereas 
the significance of IL-8 was borderline. 
 
Correlation among changes of plasma variables  
Pearson correlation analyses between changes (on-treatment minus baseline) in each log-
transformed plasma variable vs. all the others show that apart from the expected 
correlations between change in total-Cholesterol and LDL-C or triglycerides, only the 
correlations between changes in hs-CRP and changes in fibrinogen or IL-6 and between 
sCD40L and MMP-9 reached the Bonferroni threshold value of p (<0.0004) selected to 
account for 136 multiple comparisons. The positive correlation between IL-8 and MMP-9 
(r=0.38) reached p <0.001. The positive correlation between total-Cholesterol and TFPI-
total, between fibrinogen and IL-6, between TNF-α and sCD40L, and between sE-selectin 
and TFPI-free (all r  0.30) all reached p <0.01. All the other significant correlations 
observed (triglycerides vs LDL-C, r = 0.28; IL-6 vs HDL-C, r = -0.23; MMP-9 vs TNF-α, r = 
0.25; IL-18 vs sICAM-1 or sVCAM-1, r = 0.28 and 0.22, respectively;  sE-selectin vs 
triglycerides, fibrinogen and IL-8, r = 0.26, -0.22 and 0.26, respectively; and TFPI-total vs 
LDL-C, hs-CRP and sVCAM-1, all r  0.25) reached p values <0.05. 
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Changes in carotid IMT 
Table 3 shows the baseline and on-treatment values of carotid IMT as well as the yearly 
changes in log-transformed IMT for each ultrasonic variable considered. A fully significant 
regression was observed in 2 out of 4 ultrasonic variables (ICA-IMTmean, p<0.002 and 
IMTmean, p<0.004) and borderline significant for Bif-IMTmean (p=0.05). All analyses 
evaluating the relationship between changes in carotid atherosclerosis and changes in 
soluble markers were limited to the 2 variables with fully significantly regression. 
 
Correlation between changes in ICA-IMTmean, IMTmean and plasma variables measured at 
baseline 
In the Pearson correlation analysis, no correlation was observed between changes in log-
transformed ultrasonic variables (ICA-IMTmean and IMTmean) and baseline log-transformed 
values of lipids or soluble markers. The unique exception was a negative correlation 
between changes in IMTmean and baseline vWF (r=0.24; p=0.05), but the p value was 
much higher than the Bonferroni threshold (p=0.003, calculated considering 18 multiple 
comparisons). The partial-correlation analysis, adjusted for age, gender and lipids and 
pharmacological treatments yielded similar results.  
In the stepwise multiple regression analyses performed by using log-transformed 
carotid IMTs changes as dependent variable and all the other baseline log-transformed 
plasma variables (including lipids) as independent, only HDL-C inversely, but weakly, 
associated with IMTmean (β = -0.05239, SEM=0.02238, p=0.02). 
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Correlation between changes in carotid IMTs and changes in plasma variables 
No significant correlation was found between changes in lipids (triglycerides and total-, 
LDL- and HDL-Cholesterol) and changes in carotid IMTs. This was also confirmed after 
stratification in tertiles of LDL-C changes (Figure 2a and 2b); even if a weak trend seems 
to be present none of the ultrasonic endpoints tested reached statistical significance. 
Table 2 shows the Pearson and Partial (adjusted for lipids) correlation coefficients 
between changes in log-transformed ICA-IMTmean, IMTmean and changes of log-
transformed soluble markers. Positive and significant unadjusted correlations were 
observed only between ICA-IMTmean and both sE-Selectin and TFPI-total.  
After adjustment for lipids (total-Cholesterol, HDL-Cholesterol and triglycerides) we 
still found significant correlations but none reached the p<0.003 value needed to account 
for Bonferroni correction with 18 comparisons. 
 
Correlations between IMT progression and variation scores 
Table 3 shows the correlation coefficients between changes in ICA-IMTmean, IMTmean and 
changes of soluble markers combined in 5 specific scores. Excluding those with the lipid 
score, which did not correlate at all, all the other correlations reached a p value <0.05 and 
5 even <0.01, the threshold value needed using the Bonferroni correction for 5 
comparisons. No significant correlation was observed between the lipid score and any 
other score considered.  
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Discussion 
Carotid IMT regression has been observed in almost all clinical trials of high-dose 
atorvastatin (80 mg/daily).[4-6] Our data show that a moderate dose of atorvastatin (20 
mg/daily) also produces significant IMT regression in patients with post-infarction stable 
CAD, in agreement with two previous studies using a low/moderate dose of atorvastatin in 
patients with stable CAD.[7, 8] Two further studies of patients with peripheral vascular 
disease[9] or of asymptomatic patients with vascular risk factors[10] treated with 
low/moderate doses of atorvastatin both showed an atorvastatin-induced regression of 
carotid IMT.  
The MIAMI study evaluated the relationship between changes in a large panel of 
soluble markers representing inflammation/coagulation and endothelial activation 
pathways and simultaneous changes in carotid atherosclerosis. This provided a unique 
opportunity to determine whether the antiatherosclerotic effect of this statin is attributable 
to its lipid-lowering action only or whether other mechanisms are involved. Data here 
presented indicate that, even though the IMT changes did not correlate, or did so only 
poorly, with changes in any single soluble marker (or indeed with lipids), they did correlate 
with changes in combined scores of markers associated with atherogenesis.  
In acute coronary syndrome, molecules directly involved in inflammatory/thrombotic 
processes play a prominent and easily assessable role. In contrast, in post-infarction 
stable clinical conditions this role is not so prominent. This may be why their effect is 
detectable only with groups of molecules acting in concert and not with single soluble 
markers.  
The association of soluble markers with atherosclerosis progression depends on 
whether the disease is in an acute or chronic phase. The response to statins, and whether 
they are administered at high or moderate dose, may likewise depend on the phase of the 
disease. Large clinical trials have shown that high doses of statins, when administered in a 
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very early phase of acute coronary syndrome, result in a lower number of cardiovascular 
events than with placebo[11] or moderate doses[12], an effect ascribed to the reduction of 
both LDL-C and hs-CRP.[13, 14] These trials suggest that lowering LDL-C may not in itself 
be effective in the extremely early phases of acute coronary syndrome, in which an 
enhanced inflammatory state and a high thrombogenic potential coexist, making all the 
more desirable the marked decrease in hs-CRP induced by a high dose of statin. On the 
other hand, in patients with vascular risk factors[15, 16] and in conditions of post-infarction 
clinical stability,[17] low/moderate doses of statins are highly effective in reducing clinical 
events as well as in reducing the "smouldering" inflammatory and thrombogenic activity 
measured in atherosclerotic plaques of stable subjects.[18]  The data reported in the 
present study are well in line with these considerations. They confirm, in fact, that in the 
phase of post-infarction clinical stability, the rate of IMT-progression/regression, even if not 
attributable to modulation of single markers involved in atherothrombosis, is robustly 
correlated with variations of subsets of molecules involved in inflammation/coagulation or 
endothelial activation. Further, our data are consistent with the concept that the action of 
statins in plaque stabilization involves different sets of soluble molecules depending on the 
phase of the disease (acute or chronic) in which the drug is used.  
On-treatment concentrations of fibrinogen, IL-8, MMP-9, sICAM-1, sE-selectin and vWF 
were significantly lower than before treatment. Since all these molecules are involved in 
atherogenesis,[19-23] and since their changes were unrelated to changes in lipids, these 
findings suggest a pleiotropic effect of atorvastatin. By contrast, IL-6, sCD40L and TNF-α 
increased in response to treatment, (even if p values of changes in IL-6 and TNF-α did not 
reach the statistical threshold of Bonferroni correction for multiple comparison) but 
remaining within the normal range (0.4-9.5 pg/ml, 0.03-3.98 ng/ml and 0.0-4.2 pg/ml 
respectively). As far as sCD40L is concerned, since only much higher values predict 
ischemic events[24], the observed changes are probably not of clinical relevance. 
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Another apparently harmful effect observed here and in other studies with different 
statins[25-28] is the reduction of TFPI-total, which normally circulates complexed with LDL-
C.[29] However, since the anticoagulant potency of TFPI is actually restricted to TFPI-
free,[30] which was unchanged on treatment, it is unlikely that this reduction influenced the 
available anticoagulant activity. 
IL-18, sVCAM-1 and hs-CRP underwent no significant change during treatment.  
Almost all the studies published so far, whether carried out in patients with vascular risk 
factors[31-37] or in patients with acute[13, 14, 38] or stable CAD[39-41] reported a 
significant reduction of hs-CRP. To the best of our knowledge, only 1 study has shown a 
lack of effect of atorvastatin on hs-CRP[31], when baseline levels of this molecule were in 
the lowest quartile. This suggests that the statin has an effect only when patients have a 
heightened inflammatory state.  
If the relationship between baseline hs-CRP values and hs-CRP response to 
treatment is analyzed for all the studies published so far,[6, 8, 31, 38, 39, 41-45] a very 
strong linear correlation can be detected (Figure 3). In our study, hs-CRP levels fell by 
about 16%, a value in agreement with the general trend reported in the figure. From this 
figure it is also apparent that there is no relationship to the dose of atorvastatin, a 
conclusion confirmed by at least 2 studies properly designed to address this topic,[31, 46] 
but not with another 4.[6, 34, 38, 47]  
Changes in IL-6 and in hs-CRP levels showed an opposite trend. Inasmuch as IL-6 is a 
main stimulus for CRP synthesis [48-50], this observation may seem counterintuitive.  Yet,  
changes in either direction of both parameters observed in the present study did not reach 
the statistical threshold value of Bonferroni correction for multiple comparison and thus 
could be the result of chance. 
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Limitation of the study 
The main limitation of the present study is the lack of a placebo group, for ethical reasons: 
post-infarction patients cannot be left untreated. The present study could not therefore 
prove a causal effect of atorvastatin treatment and could not exclude that the observed 
changes in biomarkers and IMT were due to temporal changes or to other reasons. 
However, since it is well known that in absence of pharmacological treatments carotid IMT 
progresses, and since the concomitant treatments were unmodified at the entrance to or 
during the study, IMT regression is unlikely to have been either spontaneous or result from 
the other treatments. A spontaneous change in blood levels of soluble markers is also 
improbable since the patients were in a stable phase of the disease, at least 2 months 
after the acute coronary event. 
 
Conclusion 
In patients in a post-infarction stable condition, treated with moderate doses of 
atorvastatin, carotid IMT regression correlated with changes of inflammation, thrombosis 
and endothelial activation profiles. 
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TABLE 1. Patient’s clinical characteristics at baseline 
Characteristic Value 
Age (yrs, mean±SD) 57.5±8.1 
Gender (male/female) 72/13 
SBP (mmHg, mean±SD) 127.3±11.3 
DBP (mmHg, mean±SD) 78.3±7.0 
BMI (Kg/m2, mean±SD) 26.2±3.2 
Current smoker (%) 12.9 
Hypertension (%) 44.7 
Diabetes (%) 0* 
Parental history of CVD (%) 53.7 
History of angina (%) 7.10 
Previous coronary revascularization  
 PTCA (%) 75.3 
 CABG (%) 8.2 
Current medication and previous statin use  
ACE inhibitors (low dosage) (%) 43.0 
-blockers (%) 83.7 
Aspirin (%) 97.6 
Diuretic drugs (%) 11.8 
Antiarrhythmic drugs (%)  22.4 
Previous statin use (%) 69.0 
*exclusion criterion, CVD, cardiovascular disease; BMI, body mass index; PTCA, 
percutaneous transcatheter coronary angioplasty; CABG, coronary artery bypass graft. 
 27
Table 2: Baseline and on-treatment values of lipids and soluble markers 
Variables Baseline 
(n=85) 
On-treatment* 
(n=82) 
Change P 
Lipids     
Total-C (mg/dl) 223 (207; 250) 149 (134.5; 182) -69 (-78; -60) 0.0001
HDL-C (mg/dl) 43.5 (40; 53) 46.8 (40; 53.5) 2 (0; 4) 0.03 
LDL-C (mg/dl) 150 (129; 171) 82 (71; 104) -63 (-71; -56) 0.0001
Triglycerides (mg/dl) 150 (96; 182) 114 (83; 156) -25 (-38; -11) 0.0001
Inflammation/coagulation markers    
hs-CRP (μg/ml) 1.04 (0.52; 2.1) 0.87 (0.58; 1.75) -0.35 (-0.7; 0.0) 0.08 
IL-6 (pg/ml) 1.6 (1.1; 2.7) 1.9 (1.4; 3.2) 0.35 (-0.12; 0.82) 0.02 
IL-8 (pg/ml) 7.5 (3.5; 12.2) 4.9 (1.6; 8.6) -2.6 (-4.7; -0.6) 0.004 
IL-18 (pg/ml) 174 (141; 215) 163 (137; 200) -5.8 (-16; 4.4) 0.32 
TNF-α (pg/ml) 1.0 (0.7; 1.6) 1.3 (1.0; 1.6) -0.2 (-0.7; 0.2) 0.04 
sCD40L (ng/ml) 2.3 (1.2; 3.4) 3.1 (2.1; 4.2) 0.52 (0.01; 1.02) 0.002 
MMP-9 (ng/ml) 392 (273; 542) 352 (260; 463) -94 (-158; -30) 0.04 
Fibrinogen (mg/dl) 363 (333; 410) 327 (303; 381) -27 (-38; -16) 0.0001
TFPI-total (ng/ml) 70 (61; 80) 57 (49; 67) -12 (-15; -9) 0.0001
TFPI-free (ng/ml) 9.6 (7.9; 11.7) 9.1 (7.8; 11.1) -0.9 (-2.0; 0.2) 0.09 
Markers of endothelial activation     
sICAM-1 (ng/ml) 241 (211; 273) 219 (191; 254) -20 (-30; -11) 0.0001
sVCAM-1 (ng/ml) 552 (476; 661) 542 (474; 669) 2 (-18; 23) 0.82 
sE-selectin (ng/ml) 32 (22; 42) 22 (15; 28) -11 (-13; -9) 0.0001
vWF (IU/ml) 1.2 (1.0; 1.5) 0.9 (0.7; 1.0) -0.4 (-0.4; -0.3) 0.0001
* Average between the 12-month and the last visits. Values are median and interquartile 
range except for “change ” which are mean and 95% C.I. (log-transformed). Statistical 
significance has been evaluated with log-transformed data. In bold are p<0.004 (threshold 
for Bonferroni correction with 18 multiple comparisons). 
SBP = Systolic blood pressure, DBP = Diastolic blood pressure, BMI = body mass index.
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Table 3: Baseline and on-treatment values of carotid IMT  
 Baseline 12 month visit Last visit Yearly change in thickness P value vs zero 
CC-IMTmean 0.69 (0.65-0.75) 0.69 (0.64-0.77) 0.69 (0.65-0.74) -0.005 (-0.011, 0.001) 0.104 
Bif-IMTmean 1.04 (0.87-1.33) 1.01 (0.86-1.27) 0.97 (0.84-1.29) -0.017 (-0.035, 0.000) 0.053 
ICA-IMTmean 0.83 (0.68-1.15) 0.77 (0.66-1.08) 0.78 (0.67-1.06) -0.028 (-0.045, -0.011) 0.002 
IMTmean 0.88 (0.75-1.01) 0.86 (0.73-1.01) 0.82 (0.74-0.95) -0.013 (-0.022, -0.004) 0.004 
Values are median and interquartile range except for “Yearly change in thickness” which are mean and 95% C.I. (log-transformed). 
IMT = intima-media thickness, CC=common carotid, Bif=Bifurcation, ICA=internal carotid artery 
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Table 4. Pearson and Partial (adjusted for changes in total-C, HDL-Cholesterol, 
triglycerides and pharmacological treatments) correlation coefficients and p values 
(in lowercase) between changes in log-transformed ICA-IMTmean, IMTmean and 
changes of soluble markers (log-transformed).  
 ICA-IMTmean IMTmean 
 
 
R 
Adjusted 
R 
 
R 
Adjusted 
R 
     
TNF-α 0,06 -0,04 0,21 0,08 0,02 
sE-Selectin 0,23 0,046 0,30 0,02 0,06 0,14 
MMP-9 0,10 0,12 0,23 0,052 0,25 0,057 
IL-8 0,14 0,18 0,22 0,06 0,32 0,01 
TFPI-total 0,31 0,007 0,25 0,060 0,14 0,10 
vWF 0,17 0,26 0,050 0,21 0,07 0,27 0,04 
All plasma markers shown in Table 1 have been analyzed, but only those showing at least 
one significant correlation with at least one of IMT variables (p<0.09) are reported in the 
table. Only correlations with a p value <0.003 have to be considered as significant in order 
to taking into account for Bonferroni correction for multiple comparisons. Correlation have 
been performed after log-transformation of both ultrasonic variables and soluble markers. 
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Table 5. Correlation between changes in ICA-IMTmean, IMTmean and changes of 
soluble markers combined in 5 specific scores  
 Changes 
 
 ICA-IMTmean IMTmean 
With lipid score 
Triglycerides, LDL- and HDL-cholesterol  
0.12 
P=0.3 
0.10 
P=0.4 
With inflammation/coagulation score  
(includes changes in: hs-CRP, IL-6, IL-8, IL-18, TNF-α, sCD40L, 
MMP-9, fibrinogen, TFPI-total, TFPI-free) 
0.25 
P=0.035 
0.29 
P=0.013 
With endothelial activation score 
(includes changes in: sICAM-1, sVCAM-1, sE-selectin, vWF) 
0.40 
P=0.0007 
0.24 
P=0.04 
With soluble markers score 
(includes all variables used in the two previous scores) 
0.35 
P=0.003 
0.32 
P=0.007 
With total score  
(includes changes of all soluble markers considered and lipids) 
0.38 
P=0.001 
0.35 
P=0.003 
In each score variables expressed as delta-values (on-treatment minus baseline) were 
transformed into dichotomous variables by assigning a value of 1 for changes above the 
median, and 0 for changes equal or below (except for HDL-C for which the opposite was 
done). Each score was then computed by averaging the appropriate dichotomized 
variables. Lower values indicates a higher improvement during treatment of the specific 
“status” considered (for example a higher improvement of the inflammation/coagulation 
status), and high values a poorer improvement. 
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Figure legends 
Figure 1. Individual follow-up of patients treated with atorvastatin.  
Figure 2. Changes in log-transformed ICA-IMTmean (panel a) and IMTmean  (panel b) by 
tertiles of LDL-C reduction. IMT = intima-media thickness, ICA=internal carotid 
artery. 
Figure 3. Relationship between baseline hs-CRP values and the hs-CRP response to 
treatment in all the studies published so far. Numbers within markers are 
references. hs-CRP= high sensitive C-reactive protein  
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